Article Details
Retrieved on: 2021-07-28 11:15:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities reissued a "buy" rating and issued a $167.90 price objective on shares of Medpace in a research note on Tuesday. Finally, Zacks ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here